Abstract

HitGen, a biotech company based in China and with labs in Houston, will work with Scripps Research Institute and its affiliate, the California Institute for Biomedical Research (Calibr). The partners will use HitGen’s DNA-encoded small-molecule libraries to discover and develop oncology, regenerative medicine, and virology drugs. Scripps and Calibr will provide target materials and expertise. The alliance comes just one week after HitGen entered a multiyear drug discovery deal with Pfizer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.